Find Trials: Breast Cancer

• EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

  Condition:

  Breast Cancer

  Partner:

  Eli Lilly and Company

  Drugs:

  Selective Estrogen Receptor Degrader (LY3484356)

  Trial Name:

  J2J-MC-JZLH

  Age:

  18 years and older

  Phase:

  3

  Learn More